Rigel Pharmaceuticals, Inc.
RIGL · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Mar 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $294M | $179M | +64.1% |
| Operating income | $125M | $24.2M | +419% |
| Net income | $367M | $17.5M | +2,000% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $80.9M | $69.5M | +16.4% |
| Operating income | $17.1M | $28.4M | −39.8% |
| Net income | $13.2M | $27.9M | −52.7% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Rigel Pharmaceuticals's revenue in FY2025?
- $294M in FY2025 (Fiscal year ended Dec 31, 2025), +64.1% vs $179M a year earlier, per its 10-K filed Mar 2026.
- Was Rigel Pharmaceuticals profitable in FY2025?
- Yes: net income was $367M and operating income $125M in FY2025.
- What was Rigel Pharmaceuticals's revenue in Q3 2026?
- $80.9M (+16.4% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.